Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis

References

• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA: a cancer journal for clinicians 2016;66(2):115–132. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Landi L, D’Inca F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, et al. 2019. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J ImmunoTher Cancer. 7(1). (no pagination)(316). doi:10.1186/s40425-019-0793-8.
   PubMed Web of Science ®Google Scholar
• Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015;12(9):511–26. doi:10.1038/nrclinonc.2015.90.
   PubMed Web of Science ®Google Scholar
• Belani CP, Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer. 2002;38:13–19. doi:10.1016/S0169-5002(02)00394-X.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014;4:411.
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–57. doi:10.1001/jamaoncol.2017.4771.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. doi:10.1016/j.molmed.2014.10.009.
   PubMed Web of Science ®Google Scholar
• Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R. Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res. 2015;4:728.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387(10027):1540–50. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 2016;387(10030):1837–46. doi:10.1016/S0140-6736(16)00587-0.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al. Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Network. 2017;15(4):504–35. doi:10.6004/jnccn.2017.0050.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–37. doi:10.7326/0003-4819-144-6-200603210-00010.
   PubMed Web of Science ®Google Scholar
• Zhang G, Cheng R, Wang H, Zhang Y, Yan X, Li P, Zhang M, Zhang X, Yang J, Niu Y, et al. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. Cancer Immunol Immunother 2020;69(3):399–405.
   PubMed Web of Science ®Google Scholar
• Zhang F, Huang D, Li T, Zhang S, Wang J, Zhang Y, Wang G, Zhao Z, Ma J, Wang L, et al. Anti-PD-1 therapy plus chemotherapy and/or Bevacizumab as second line or later treatment for patients with advanced non-small cell lung cancer. J Cancer. 2020;11(3):741–49. doi:10.7150/jca.37966.
   PubMed Web of Science ®Google Scholar
• Ruiz‐Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain‐Barrón ZL, Barrón F, Ricaurte L, Bravo‐Garzón MA, Mas L, et al. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thoracic Cancer. 2020;11(2):353–61. doi:10.1111/1759-7714.13272.
   PubMed Web of Science ®Google Scholar
• Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, et al. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer. 2020;140:8–18. doi:10.1016/j.lungcan.2019.11.014.
   PubMed Web of Science ®Google Scholar
• Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, et al. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Invest New Drugs. 2020;38(1):211–18. doi:10.1007/s10637-019-00882-5.
   PubMed Web of Science ®Google Scholar
• Ruiz-Banobre J, Areses-Manrique MC, Mosquera-Martinez J, Cortegoso A, Afonso-Afonso FJ, de Dios-álvarez N, Fernández-Núñez N, Azpitarte-Raposeiras C, Amenedo M, Santomé L, et al. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2019;8(6):1078–85. doi:10.21037/tlcr.2019.11.07.
   PubMed Web of Science ®Google Scholar
• Ren F, Zhao T, Liu B, Pan L. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). Onco Targets Ther. 2019;12:4235–44. doi:10.2147/OTT.S199176.
   PubMed Web of Science ®Google Scholar
• Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, et al. Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort. Cancers. 2019;11(12):1954. (no pagination)(1954). doi:10.3390/cancers11121954.
   PubMed Web of Science ®Google Scholar
• Lang D, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, Akbari K, Granitz M, Hutarew G, Kaiser B et al: Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. Targeted oncology. 2019;14(6):707–717.
   PubMed Web of Science ®Google Scholar
• Kuo CHS, Wang CC, Huang YC, Pavlidis S, Liu C-Y, Ko H-W, Chung F-T, Lin T-Y, Wang C-L, Guo Y-K, et al. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. Thoracic Cancer. 2019;10(5):1158–66. doi:10.1111/1759-7714.13057.
   PubMed Web of Science ®Google Scholar
• Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thoracic Oncol. 2019;14(7):1244–54. doi:10.1016/j.jtho.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Gao G, Jia K, Zhao S, Li X, Zhao C, Jiang T, Su C, Ren S, Zhou F, Zhou C, et al. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(6):920–28. doi:10.21037/tlcr.2019.11.25.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer. 2019;128:105–12. doi:10.1016/j.lungcan.2018.12.017.
   PubMed Web of Science ®Google Scholar
• Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, et al. Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study. Clin Lung Cancer. 2019;20(3):208–14.e2. doi:10.1016/j.cllc.2018.04.021.
   PubMed Web of Science ®Google Scholar
• Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145:1613–23. doi:10.1007/s00432-019-02899-y.
   PubMed Web of Science ®Google Scholar
• Tournoy KG, Thomeer M, Germonpre P, Derijcke S, De Pauw R, Galdermans D, Govaert K, Govaerts E, Schildermans R, Declercq I, et al. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer. 2018;115:49–55. doi:10.1016/j.lungcan.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, Taniguchi Y, Shiroyama T, Isa S-I, Nishino K, et al. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. PLoS ONE [Electronic Resource]. 2018;13(2):e0192227. doi:10.1371/journal.pone.0192227.
   PubMed Web of Science ®Google Scholar
• Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim D-W, Heo DS, Lee JS. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother. 2018;67(3):459–70. doi:10.1007/s00262-017-2092-x.
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Suzuki H, Tamiya M, TAMIYA A, TANAKA A, OKAMOTO N, NAKAHAMA K, TANIGUCHI Y, ISA S-I, INOUE T, et al. Clinical characteristics of liver metastasis in nivolumab-treated patients with non-small cell lung cancer. Anticancer Res. 2018;38(8):4723–29. doi:10.21873/anticanres.12779.
   PubMed Web of Science ®Google Scholar
• Garde-Noguera J, Martin-Martorell P, De Julian M, Perez-Altozano J, Salvador-Coloma C, García-Sanchez J, Insa-Molla A, Martín M, Mielgo-Rubio X, Marin-Liebana S, et al. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. Clin Transl Oncol. 2018;20(8):1072–79. doi:10.1007/s12094-017-1829-5.
   PubMed Web of Science ®Google Scholar
• Dumenil C, Massiani MA, Dumoulin J, Giraud V, Labrune S, Chinet T, Giroux Leprieur E. Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE [Electronic Resource]. 2018;13(4):e0195945. doi:10.1371/journal.pone.0195945.
   PubMed Web of Science ®Google Scholar
• Dudnik E, Moskovitz M, Daher S, Shamai S, Hanovich E, Grubstein A, Shochat T, Wollner M, Bar J, Merimsky O, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer. 2018;126:217–23. doi:10.1016/j.lungcan.2017.11.015.
   PubMed Web of Science ®Google Scholar
• Funazo T, Nomizo T, Kim YH. Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thoracic Oncol. 2017;12(9):e140–e1. doi:10.1016/j.jtho.2017.04.027.
   PubMedGoogle Scholar
• Detterbeck FC, Tanoue LT, Boffa DJ. Anatomy, biology and concepts, pertaining to lung cancer stage classification. J Thoracic Oncol. 2009;4(4):437–43. doi:10.1097/JTO.0b013e31819852ed.
   PubMed Web of Science ®Google Scholar
• Oikawa A, Takahashi H, Ishikawa H, Kurishima K, Kagohashi K, Satoh H. Application of conditional probability analysis to distant metastases from lung cancer. Oncol Lett. 2012;3(3):629–34. doi:10.3892/ol.2011.535.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA, Barón AE, Franklin WA, Aisner DL, et al. Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer. Cancer. 2012;118(18):4502–11. doi:10.1002/cncr.27409.
   PubMed Web of Science ®Google Scholar
• Patel RR, Mehta MP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res. 2007;13(6):1675–83. doi:10.1158/1078-0432.CCR-06-2489.
   PubMed Web of Science ®Google Scholar
• Schapira E, Hubbeling H, Yeap BY, Mehan WA, Shaw AT, Oh K, Gainor JF, Shih HA. Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys. 2018;101(3):624–29. doi:10.1016/j.ijrobp.2018.02.175.
   PubMed Web of Science ®Google Scholar
• Crino L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019;129:35–40. doi:10.1016/j.lungcan.2018.12.025.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA oncol. 2017;3(6):827–31. doi:10.1001/jamaoncol.2016.3834.
   PubMed Web of Science ®Google Scholar
• Shepard MJ, Xu Z, Donahue J, Eluvathingal Muttikkal TJ, Cordeiro D, Hansen L, Mohammed N, Gentzler RD, Larner J, Fadul CE, et al. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg. 2019:1–8. doi:10.3171/2019.4.JNS19822
   PubMedGoogle Scholar
• Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008;466(3):729–36. doi:10.1007/s11999-007-0051-0.
   PubMed Web of Science ®Google Scholar
• Raubenheimer E, Noffke C. Pathogenesis of bone metastasis: a review. J Oral Pathol Med. 2006;35(3):129–35. doi:10.1111/j.1600-0714.2006.00360.x.
   PubMed Web of Science ®Google Scholar
• Santini D, Pantano F, Vincenzi B, Tonini G, Bertoldo F. The role of bone microenvironment, vitamin D and calcium. Recent Results Cancer Res 2012;192:33–64
   PubMedGoogle Scholar
• Yang N, Jiang Y, Zhang H, Sun B, Hou C, Zheng J, Liu Y, Zuo P. Active targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasis. Mol Pharm. 2015;12(1):232–39. doi:10.1021/mp500568z.
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Annals Oncol. 2018;29(4):959–65. doi:10.1093/annonc/mdy041.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. doi:10.1056/NEJMoa1709030.
   PubMed Web of Science ®Google Scholar
• Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK, Wolchok JD, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J clin oncol. 2020;38(15):1655–63. doi:10.1200/JCO.19.01464.
   PubMedGoogle Scholar
• Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67. doi:10.1016/j.ctrv.2017.01.007.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, et al. Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study. JAMA oncol. 2018;4(4):537–44. doi:10.1001/jamaoncol.2017.5440.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020;38(26):2960–70.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Kang Y-K, Park H, Uronis HE, Lee K-W, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020;21(8):1066–76. doi:10.1016/S1470-2045(20)30326-0.
   PubMed Web of Science ®Google Scholar